Abstracts tagged "Biomarkers"

Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Antonio Carriero ¹, Giuseppina Abignano ², MIchelle Hutchinson ³, Karri Ballard ⁴ and Francesco Del Galdo⁵, ¹University of Leeds, Leeds, England, United Kingdom, ²3Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, ³University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, ⁴Myriad RBM, austin, TX, ⁵University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
Abstract Number: 784 • 2019 ACR/ARP Annual Meeting
Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Cristina Segu-Verges¹, Mireia Coma ¹, Christoph Kessel ², Serge Smeets ³, Dirk Foell ² and Anna Aldea ⁴, ¹Anaxomics, Barcelona, Catalonia, Spain, ²University Hospital Muenster, Muenster, Germany, ³Novartis, Amsterdam, Netherlands, ⁴Novartis, Barcelona, Catalonia, Spain
Background/Purpose: Systemic JIA (sJIA) and Adult Onset Still’s Disease may represent a disease continuum1 of the same autoinflammatory disorder, Still’s Disease. Current challenges in its…
Abstract Number: 1889 • 2019 ACR/ARP Annual Meeting
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up
Julio Ramirez¹, Andrea Cuervo Aguilera ², Raquel Celis ³, Virginia Ruiz-Esquide ³, Raul Castellanos-Moreira ⁴, Jose Gomez-Puerta ⁵, Raimon Sanmarti ⁵ and Juan Cañete ⁵, ¹Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²Hospital Clínic Barcelona, Spain, Barcelona, Spain, ³Hospital Clínic, Barcelona, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: To search biomarkers of clinical relapse and radiological progression in patients with RA in clinical remissionMethods: RA patients in clinical remission (defined as DAS28-ESR…
Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 1907 • 2019 ACR/ARP Annual Meeting
Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Jacques-Eric Gottenberg¹, Sumanta Mukherjee ², Marleen Nys ³, Robert Wong ⁴, Hendrika Bootsma ⁵ and Neelanjana Ray ⁴, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁴Bristol-Myers Squibb, Princeton, ⁵University of Groningen, Groningen, Netherlands
Background/Purpose: Chemokine (C-X-C motif) ligand 13 (CXCL13), produced by follicular helper T (Tfh) cells, plays a pivotal role in B-cell homing and activation in germinal…
Abstract Number: 1020 • 2019 ACR/ARP Annual Meeting
NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus
Ming-Han Chen¹, Yen-Po Tsao ¹ and Szu-Ting Chen ², ¹Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ²Institutes of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (Republic of China)
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease with diverse etiological factors. It was well recognized that interferon (IFN) signature did the perpetration…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 1054 • 2019 ACR/ARP Annual Meeting
Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis
Kristina Clark¹, Corrado Campochiaro ¹, Katherine Nevin ², Eszter Csomor ², Nicholas Galwey ², Mary Morse ², Nicolas Wisniacki ², Shaun Flint ², Voon Ong ³, Emma Derrett-Smith ¹ and Christopher Denton ⁴, ¹University College London, London, United Kingdom, ²GlaxoSmithKline, Stevenage, United Kingdom, ³UCL Medical School, Royal Free Campus, London, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is characterised by autoimmunity, fibrosis and vasculopathy. There is striking heterogeneity in skin fibrosis that is likely to reflect the balance…
Abstract Number: 1915 • 2019 ACR/ARP Annual Meeting
Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis
Gregg Silverman¹, Doua Azzouz ¹, Caroline Grönwall ², Iva Gunnarsson ³ and Elisabet Svenungsson ⁴, ¹NYU School of Medicine, New York, NY, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ³Karolinska Institute, Stockholm, Stockholms Lan, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is the archetypic systemic autoimmune disease, for which there is mounting evidence for roles for intestinal bacteria in the development…
Abstract Number: 1226 • 2019 ACR/ARP Annual Meeting
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Daisy Vedder ¹, Martijn Gerritsen ¹, Mike Nurmohamed ², Ronald van Vollenhoven ³ and Christian Lood⁴, ¹Amsterdam Rheumatology & immunology Center / Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴University of Washington, Seattle, WA
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has…
Abstract Number: 1945 • 2019 ACR/ARP Annual Meeting
Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients
Ankita Singh¹, Harikrishnan Nair ², Vikas Gupta ², Pradeepta Sekhar ², Ramnath Misra ³ and Amita Aggarwal ⁴, ¹Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Methotrexate (MTX) is first line therapy to treat rheumatoid arthritis (RA) patients. However, the response is variable with 50-60% showing response and this variability…
Abstract Number: 1303 • 2019 ACR/ARP Annual Meeting
Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA
Dawn McGuire¹, Michael Bowes ², Alan Brett ², Neil Segal ³, Meghan Miller ⁴, David Rosen ⁴ and Yoshinari Kumagai ⁴, ¹OrthoTrophix, Orinda, CA, ²Imorphics, Manchester, England, United Kingdom, ³University of Kansas Medical Center, Kansas City, KS, ⁴OrthoTrophix, Oakland, CA
Background/Purpose: Pathological bone shape changes in the femur precede cartilage changes in knee OA and predict disease onset and progression to joint failure (Neogi 2013;…
Abstract Number: 2187 • 2019 ACR/ARP Annual Meeting
A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment
Yunyun Luo ¹, Jonathan Samuels ², Svetlana Krasnokutsky ³, Inger Byrjalsen ¹, Jeppe Andersen ⁴, Asger Bihlet ⁵, Yi He ¹, Morten Karsdal ⁶, Steven Abramson ⁷, Mukundan Attur ³ and Anne Bay-Jensen¹, ¹Nordic Bioscience, Herlev, Denmark, ²NYU Langone Medical Center, New Yort, NY, ³NYU School of Medicine and NYU Langone Orthopedic Hospital, New York City, NY, ⁴Nordic Bioscience, Clinical development, Herlev, Denmark, ⁵Nordic Bioscience Clinical Development, Herlev, Denmark, ⁶Nordic Bioscience, Copenhagen, Denmark, ⁷NYU School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: Osteoarthritis (OA) is a highly heterogeneous disease, which suggest that multiple endotypes exist. Identification and characterization of such endotypes may assist in precision medicine…
Abstract Number: 1357 • 2019 ACR/ARP Annual Meeting
Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity
Joshua Baker¹, Jeffrey Curtis ², David Chernoff ³ and Michael George ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²University of Alabama at Birmingham, Birmingham, AL, ³Myriad Genetics, Inc, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Obesity and excess adiposity influence inflammatory markers and bias assessments of disease activity, most notably among women. A leptin-adjusted multi-biomarker disease activity (MBDA-LA) score…
Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Melanie Hagen¹, Koray Tascilar ², Michaela Reiser ³, Judith Haschka ⁴, Arnd Kleyer ⁵, Larissa Valor ⁶, Bernhard Manger ⁷, Georg Schett ⁸ and Jürgen Rech ⁹, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Karl Landsteiner Institute for Gastroenterology and Rheumatology, St. Vincent Hospital Vienna, II Medical Department, Vienna, Austria, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ⁷Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].